DGAP-News

SuppreMol GmbH: Baxter's Bioscience Business acquires biopharmaceutical Company SuppreMol - Seite 2

biotech companies. Working with Baxter, a global immunology leader, is the
ideal setting for SuppreMol's promising therapeutic projects to deliver on
our most ambitious goal to treat important autoimmune diseases and severe
allergies," said Klaus Schollmeier, Ph.D., CEO of SuppreMol.

"SuppreMol has built a rare combination of leading science and promising
therapeutic assets. We are proud that this important work will now continue
at Baxter BioScience," said Thomas Hecht, MD, Chairman of the Advisory
Board of SuppreMol.

About Baxter BioScience
Baxter BioScience is a leading provider of therapeutic treatments that
save, sustain and improve the lives of people with rare conditions, chronic
diseases or limited treatment options. Supported by advanced technical and
manufacturing expertise, Baxter BioScience has a broad pipeline built on a
legacy of innovation in bleeding disorders and immunology and is expanding
to address emerging opportunities in technology platforms such as gene
therapy and biosimilars. By mid-2015, Baxter expects to establish the
BioScience business as a separate, publicly traded, innovation-oriented
biopharmaceutical company.

About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops, manufactures
and markets products that save and sustain the lives of people with
hemophilia, immune disorders, cancer, infectious diseases, kidney disease,
trauma and other chronic and acute medical conditions. As a global,
diversified healthcare company, Baxter applies a unique combination of
expertise in medical devices, pharmaceuticals and biotechnology to create
products that advance patient care worldwide.

About SuppreMol GmbH
SuppreMol GmbH is a privately held biopharmaceutical company developing
novel therapeutics for the treatment of autoimmune and allergic diseases.
The company is pioneering the development of a soluble Fc-gamma receptor
IIB (sFcgRIIB), which is a recombinant autologous therapeutic protein with
a specific immunoregulatory potential. The company is developing this
sFcgRIIB clinically for the treatment of certain autoimmune conditions
including systemic lupus erythematosus (SLE). SuppreMol's preclinical
pipeline includes two antibody development programs which utilize the
inhibitory effect of FcgRIIB and are suitable for alternative treatment
strategies in autoimmune disease and allergy. SuppreMol was founded as a
spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize
Laureate in Chemistry 1988, at the Max Planck Institute for Biochemistry in
Martinsried, Germany. Major shareholders in the company include MIG Fonds,
Santo Holding GmbH, BioMedInvest AG I and FCP Biotech Holding GmbH along
with KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society, and
Z-Cube.


Contact

SuppreMol GmbH

Dr. Klaus Schollmeier
Chief Executive Officer

Tel: [phone]
E-mail: [e-mail]
www.suppremol.com

Media Contact

MC Services AG

Raimund Gabriel
Managing Partner

Tel: [phone]
E-mail: [e-mail]



---------------------------------------------------------------------

04.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


329821 04.03.2015